Skip to main content
. 2019 Apr 3;3(7):1084–1091. doi: 10.1182/bloodadvances.2018028035

Figure 2.

Figure 2.

Outcomes in patients with VAEs depending upon management strategy of first VAE. *Median follow-up, 27.5 months (range, 19-56 months) after first VAE. †Median follow-up, 35 months (range, 16-45 months) after first VAE. ‡Stopped because of resistance (at 6 and 12 months), metabolic syndrome (at 36 months), and interaction with melanoma treatment (at 15 months). §Follow-up of 16 and 35 months after first VAE. Both patients experienced ACS as the first VAE. Patient 1 was treated with aspirin alone, and patient 2 commenced aspirin, clopidogrel, and rosuvastatin. ‖Median follow-up, 26 months (range, 20-73 months) after first VAE. ¶Died as a result of metastatic melanoma.